哌拉西林钠他唑巴坦钠治疗老年呼吸道感染的价值  

The value of piperacillin sodium and tazobactam sodium in the treatment of respiratory tract infections in the elderly

作　　者：赵媛 宁欣 刘晶 ZHAO Yuan;NING Xin;LIU Jing(Liaoning Jinqiu Hospital,Shenyang 110000,China)

机构地区：[1]辽宁省金秋医院,110000 [2]锦州医科大学附属第一医院,121001

出　　处：《中国实用医药》2024年第14期107-109,共3页China Practical Medicine

摘　　要：目的探析哌拉西林钠他唑巴坦钠治疗老年呼吸道感染的临床效果。方法68例老年呼吸道感染患者,随机分为对照组和观察组,每组34例。对照组采用美洛西林钠舒巴坦钠治疗,观察组给予哌拉西林钠他唑巴坦钠治疗。比较两组临床疗效、临床病症改善情况(退热时间、止咳时间、咽痛缓解时间、咽部充血消失时间)、不良反应(肌肉痉挛、皮疹、腹泻、发热)发生情况以及治疗前后血浆白细胞计数、炎症因子[C反应蛋白(CRP)、降钙素原(PCT)]、细胞免疫功能[CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)、自然杀伤(NK)细胞]。结果观察组总有效率94.12%高于对照组的76.47%,差异有统计学意义(χ^(2)=4.221,P<0.05)。观察组患者退热时间(2.38±0.36)d、止咳时间(3.51±0.47)d、咽痛缓解时间(3.89±0.67)d、咽部充血消失时间(3.86±0.60)d均短于对照组的(3.19±0.46)、(5.11±0.59)、(5.69±0.73)、(5.72±0.67)d,差异有统计学意义(t=8.086、12.368、10.593、12.059,P<0.05)。治疗后,观察组患者白细胞计数(6.06±0.80)×10^(9)/L、CRP(6.51±1.28)mg/L、PCT(0.34±0.04)ng/ml均低于对照组的(8.70±1.12)×10^(9)/L、(8.59±2.07)mg/L、(0.59±0.10)ng/ml,CD4^(+)(42.12±2.62)%、CD4^(+)/CD8^(+)(1.28±0.29)均高于对照组的(36.80±2.94)%、(1.13±0.26),差异有统计学意义(P<0.05),两组患者的CD3^(+)、CD8^(+)、NK细胞比较,差异无统计学意义(P>0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(χ^(2)=3.981,P<0.05)。结论在老年呼吸道感染疾病的临床治疗中,应用哌拉西林钠他唑巴坦钠可以对疾病的恢复起到促进作用,并有利于恢复白细胞计数,降低炎性反应,促进细胞免疫功能的改善,加快临床症状的缓解,临床效果明显,安全性较高,值得临床推广。Objective To explore the clinical effect of piperacillin sodium and tazobactam sodium in the treatment of respiratory tract infections in the elderly.Methods A total of 68 elderly patients with respiratory tract infection were randomly divided into a control group and an observation group,each with 34 cases.The control group was treated with mezlocillin sodium and sulbactam sodium,and the observation group was treated with piperacillin sodium and tazobactam sodium.Both groups were compared in terms of clinical efficacy,clinical symptom improvement(time for fever relief,cough relief,pharyngeal pain relief,and pharyngeal congestion disappearance),adverse reactions(muscle spasms,rash,diarrhea,fever),plasma leukocyte count,inflammatory factors[C-reactive protein(CRP)and procalcitonin(PCT)],cellular immune function[CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)and natural killer(NK)cell]before and after treatment.Results The total effective rate of the observation group was 94.12%,which was higher than 76.47%of the control group,and the difference was statistically significant(χ^(2)=4.221,P<0.05).In observation group,the time for fever relief,cough relief,pharyngeal pain relief,and pharyngeal congestion disappearance were(2.38±0.36),(3.51±0.47),(3.89±0.67),and(3.86±0.60)d,which were shorter than(3.19±0.46),(5.11±0.59),(5.69±0.73),and(5.72±0.67)d in the control group,and the difference was statistically significant(t=8.086,12.368,10.593,12.059;P<0.05).After treatment,the observation group had white blood cell count of(6.06±0.80)×10^(9)/L,CRP of(6.51±1.28)mg/L and PCT of(0.34±0.04)ng/ml,which were lower than(8.70±1.12)×10^(9)/L,(8.59±2.07)mg/L and(0.59±0.10)ng/ml in the control group;the observation group had CD4^(+)of(42.12±2.62)%and CD4^(+)/CD8^(+)of(1.28±0.29),which were higher than(36.80±2.94)%and(1.13±0.26)in the control group;the difference was statistically significant(P<0.05).There was no significant difference in CD3^(+),CD8^(+)and NK cell between the two groups(P>0.05).The incidence of adverse re

关 键 词：哌拉西林钠他唑巴坦钠 老年 呼吸道感染 炎症因子 细胞免疫功能 临床效果 

分 类 号：R56[医药卫生—呼吸系统]